Lyon and New York, July 31, 2020 – The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED, eligible for PEA-PME, and OTCQX: MRNTF), pioneer in the digital transformation of spine surgery thanks to UNiD (TM) ASI (Adaptive Spine Intelligence) technology ), implementing Artificial Intelligence, Predictive Modeling and Personalized Spinal Implants, announces the appointment of an independent expert.

Following the announcement of the voluntary and friendly cash tender offer for the shares of Medicrea International (Euronext Growth Paris: FR0004178572 – ALMED, eligible for PEA-PME, and OTCQX: MRNTF) (the “Company” ) by Medtronic (NYSE: MDT), the details of which appear in the press release dated July 15, 2020 (the “Offer”) and due to the existence of conflicts of interest related to the Offer within the Board of Directors of the Company, it was decided to appoint an independent expert for the preparation of the report on the financial conditions of the Offer in accordance with the provisions of articles 261-1 I et seq. general regulations of the Autorité des marchés financiers (the “AMF”) and AMF instruction DOC-2006-08, as amended on February 10, 2020. The report will contain an assessment of the Company targeted by the Offer based on on a multi-criteria approach including the implementation of evaluation methods and the referral review valuation erences.

The Board of Directors, in accordance with article 261-1 III. of the AMF General Regulations, on July 20, 2020, set up an ad hoc committee, composed of the following members:

– François-Régis ORY – Independent Director – Chairman of the ad hoc committee

– Patrick BERTRAND – Administrator

– Christophe BONNET – Independent Director

It is specified that the purpose of the ad hoc committee is to propose the appointment of an independent expert to the Board of Directors, to monitor the expert’s work and to prepare a draft reasoned opinion.

The Board of Directors, on the proposal of the ad hoc committee, appointed Orfis as independent expert responsible for preparing the report on the fairness of the Offer.

The independent expert’s report and the reasoned opinion of the Company’s Board of Directors will appear in the draft response document which will be drawn up and submitted for approval by the AMF.


By combining the analytical power of IT tools and big data and deep learning technologies, with the mass of clinical data that the Company collects, as well as with available scientific data, MEDICREA® is well positioned to enhance the effectiveness of spine treatments by reducing surgical complications and limiting the time spent in the operating room with a view to predictive medicine.

Operating in a 10 billion dollar market, MEDICREA® is a Lyon SME with 175 people, including 35 within its subsidiary Medicrea USA Corp. based in New York. The Company has its own ultra-modern production unit in Lyon, dedicated to the machining and development of custom implants by 3D printing from titanium powder.

For more information, please visit:

Communicate with MEDICREA®




Founder, Chairman and CEO


Financial director

Phone. : +33 (0) 4 72 01 87 87

MEDICREA® is listed on

EURONEXT Growth Paris

EnterNext Index PEA PME 150

ISIN: FR 0004178572

Mnemonic: ALMED


MEDICREA® actions are

negotiable on

OTCQX Best Market

Symbols: MRNTF

This publication has the service “Actusnews SECURITY MASTER“.
SECURITY MASTER Key : lG9saZZnaJzJlmudkpmZbGqXl2yVyGWWbJTJmGNumJ6Ua29jypxiaMmZZm9lmm5n
– To check this key:

Regulated information:
Press releases published during a public takeover bid:
– Takeover bid Other press releases

Full and original press release in PDF format: